Medians Pharma Private Limited
Markets pharmaceutical and medical products such as capsules, tablets, and syrup.
2016 | Aurangabad, Maharashtra (India) | Active
Medians Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 81.45%
- Ebitda 86.14%
- Net Worth -0.90%
- Total Assets -3.42%
About Medians Pharma
Medians Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 February 2016 (Nine years 15 days old ). Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mangesh Gaikwad, Nikhil Jadhav, Sushil Marathe, and One other member serve as directors at the Company.
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74120MH2016PTC273089
- Company No.
273089
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Medians Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mangesh Gaikwad  | Director | 12-Feb-2016 | Current |
| Nikhil Jadhav | Director | 12-Feb-2016 | Current |
| Sushil Marathe | Director | 12-Feb-2016 | Current |
| Prashant Patil | Director | 01-Jan-2018 | Current |
Financial Performance of Medians Pharma.
Medians Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 81.45% increase in profit. The company's net worth dipped by a decrease of 0.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medians Pharma?
In 2019, Medians Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Medgrin Agrotech And Farming (Opc) Private Limited
Mangesh Gaikwad is a mutual person
- Shree Samarth Healthcare Foundation
Nikhil Jadhav is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medians Pharma?
Unlock and access historical data on people associated with Medians Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medians Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medians Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.